225 related articles for article (PubMed ID: 3121363)
21. Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
Marshall PJ; Griswold DE; Breton J; Webb EF; Hillegass LM; Sarau HM; Newton J; Lee JC; Bender PE; Hanna N
Biochem Pharmacol; 1991 Jul; 42(4):813-24. PubMed ID: 1907824
[TBL] [Abstract][Full Text] [Related]
22. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.
Tateson JE; Randall RW; Reynolds CH; Jackson WP; Bhattacherjee P; Salmon JA; Garland LG
Br J Pharmacol; 1988 Jun; 94(2):528-39. PubMed ID: 2840160
[TBL] [Abstract][Full Text] [Related]
23. A new antiinflammatory compound, timegadine (N-cyclohexyl-N"-4-[2-methylquinolyl]-N'-2-thiazolylguanidine), which inhibits both prostaglandin and 12-hydroxyeicosatetraenoic acid (12-HETE) formation.
Ahnfelt-Rønne I; Arrigoni-Martelli E
Biochem Pharmacol; 1980 Dec; 29(24):3265-9. PubMed ID: 6783045
[No Abstract] [Full Text] [Related]
24. Lipoxygenase pathways of macrophages.
Bonney RJ; Opas EE; Humes JL
Fed Proc; 1985 Nov; 44(14):2933-6. PubMed ID: 2996948
[TBL] [Abstract][Full Text] [Related]
25. Lung cancer cell lines inhibit leukotriene B4 production by human polymorphonuclear leukocytes at the level of phospholipase A2.
Abe M; Matsuki H; Domae M; Kuwata H; Kudo I; Nakanishi Y; Hara N; Mitsuyama T; Furukawa T
Am J Respir Cell Mol Biol; 1996 Nov; 15(5):565-73. PubMed ID: 8918363
[TBL] [Abstract][Full Text] [Related]
26. Metabolism of arachidonic acid through the 5-lipoxygenase pathway in normal human peritoneal macrophages.
Laviolette M; Carreau M; Coulombe R; Cloutier D; Dupont P; Rioux J; Braquet P; Borgeat P
J Immunol; 1988 Sep; 141(6):2104-9. PubMed ID: 2844895
[TBL] [Abstract][Full Text] [Related]
27. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
28. Modulation by hydroxyeicosatetraenoic acids (HETEs) of arachidonic acid metabolism in mouse resident peritoneal macrophages.
Chang J; Lamb B; Marinari L; Kreft AF; Lewis AJ
Eur J Pharmacol; 1985 Jan; 107(2):215-22. PubMed ID: 3920057
[TBL] [Abstract][Full Text] [Related]
29. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products.
Tornhamre S; Edenius C; Smedegård G; Sjöquist B; Lindgren JA
Eur J Pharmacol; 1989 Oct; 169(2-3):225-34. PubMed ID: 2572437
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin.
Peters-Golden M; Shelly C
Biochem Pharmacol; 1989 May; 38(10):1589-95. PubMed ID: 2499339
[TBL] [Abstract][Full Text] [Related]
31. 1,2-Dihydro-1-oxopyrrolo[3,2,1-kl]phenothiazine-2-carboxamides and congeners, dual cyclooxygenase/5-lipoxygenase inhibitors with antiinflammatory activity.
Mylari BL; Carty TJ; Moore PF; Zembrowski WJ
J Med Chem; 1990 Jul; 33(7):2019-24. PubMed ID: 2113951
[TBL] [Abstract][Full Text] [Related]
32. Lipoxygenase pathway in islet endocrine cells. Oxidative metabolism of arachidonic acid promotes insulin release.
Metz S; VanRollins M; Strife R; Fujimoto W; Robertson RP
J Clin Invest; 1983 May; 71(5):1191-205. PubMed ID: 6406544
[TBL] [Abstract][Full Text] [Related]
33. Direct inhibition of cyclooxygenase pathway in platelets by tixocortol 21-pivalate: comparison with related structures, steroidal and non steroidal anti-inflammatory drugs.
Lelievre V; Martin B; Bure J; Junien JL
Agents Actions; 1988 Jun; 24(1-2):179-86. PubMed ID: 3136624
[TBL] [Abstract][Full Text] [Related]
34. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.
Tries S; Neupert W; Laufer S
Inflamm Res; 2002 Mar; 51(3):135-43. PubMed ID: 12005204
[TBL] [Abstract][Full Text] [Related]
35. Multiple effects of a new anti-inflammatory agent, timegadine, on arachidonic acid release and metabolism in neutrophils and platelets.
Ahnfelt-Rønne I; Arrigoni-Martelli E
Biochem Pharmacol; 1982 Aug; 31(16):2619-24. PubMed ID: 6291540
[TBL] [Abstract][Full Text] [Related]
36. Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids.
Moroney MA; Alcaraz MJ; Forder RA; Carey F; Hoult JR
J Pharm Pharmacol; 1988 Nov; 40(11):787-92. PubMed ID: 2907559
[TBL] [Abstract][Full Text] [Related]
37. Variabilin: a dual inhibitor of human secretory and cytosolic phospholipase A2 with anti-inflammatory activity.
Escrig V; Ubeda A; Ferrandiz ML; Darias J; Sanchez JM; Alcaraz MJ; Paya M
J Pharmacol Exp Ther; 1997 Jul; 282(1):123-31. PubMed ID: 9223548
[TBL] [Abstract][Full Text] [Related]
38. Cellular and topical in vivo inflammatory murine models in the evaluation of inhibitors of phospholipase A2.
Glaser KB; Sung ML; Hartman DA; Lock YW; Bauer J; Walter T; Carlson RP
Skin Pharmacol; 1995; 8(6):300-8. PubMed ID: 8688196
[TBL] [Abstract][Full Text] [Related]
39. 2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity.
Batt DG; Maynard GD; Petraitis JJ; Shaw JE; Galbraith W; Harris RR
J Med Chem; 1990 Jan; 33(1):360-70. PubMed ID: 2104936
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological properties of a new anti-inflammatory compound, alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolacto ne (KME-4), and its inhibitory effects on prostaglandin synthetase and 5-lipoxygenase.
Hidaka T; Hosoe K; Ariki Y; Takeo K; Yamashita T; Katsumi I; Kondo H; Yamashita K; Watanabe K
Jpn J Pharmacol; 1984 Sep; 36(1):77-85. PubMed ID: 6438380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
